Successful treatment of recalcitrant palmoplantar psoriasis with etanercept.
Palmoplantar psoriasis is a disabling condition characterized by recurrent crops of sterile pustules with associated erythema, fissuring, and scaling. Genetic and environmental factors have been implicated in its etiology. Topical treatments are frequently ineffective. Other treatment options include systemic retinoids, psoralen-UVA (PUVA), and a combination of both. We report a case of successful treatment of recalcitrant palmoplantar psoriasis with etanercept in a 59-year-old woman unresponsive to other treatment modalities.
Weinberg
Jeffrey M
JM
Department of Dermatology, St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA. jmw27@columbia.edu
D000279:Administration, Cutaneous; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D000068800:Etanercept; D005260:Female; D005533:Foot Dermatoses / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D006229:Hand Dermatoses / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011565:Psoriasis / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence
D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000068800:Etanercept